Kanilad Os (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilizing hyper‑excitable membranes and decreasing repetitive firing. This mechanism helps to suppress the abnormal electrical activity that leads to seizures.

The appropriate dose of Kanilad Os is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. Patients should follow the individualized dosing regimen provided by their healthcare professional.

Safety data for lacosamide in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss options with their healthcare provider.

To request Kanilad Os, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide differs from many antiepileptics by specifically enhancing slow inactivation of sodium channels, offering a distinct mechanism that can be effective when other drugs fail. It is generally well‑tolerated, but the choice of therapy depends on seizure type, patient comorbidities, and individual response.

Kanilad Os should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children and do not store in humid or excessively hot environments.

Kanilad Os is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities like PR‑interval prolongation, and psychiatric effects such as suicidal thoughts. Patients should seek immediate medical attention if they experience rash, chest pain, palpitations, or mood changes.

Kanilad Os is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that could increase toxicity.